Related Experiment Video

Updated: Mar 15, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.1K

Intravenous β-blockers for patients undergoing primary percutaneous coronary intervention: A meta-analysis of

Islam Y Elgendy1, Akram Y Elgendy1, Ahmed N Mahmoud1

  • 1Department of Medicine, University of Florida, Gainesville, FL, USA.

International Journal of Cardiology
|September 2, 2016
PubMed

Insights

Intravenous beta-blockers are safe for ST-elevation myocardial infarction patients undergoing primary PCI and reduce ventricular arrhythmias. Further research is needed to confirm their efficacy on other outcomes.

Area of Science:

  • Cardiology
  • Clinical Trials
  • Pharmacology

Background:

  • Efficacy and safety of intravenous beta-blockers in ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) remain unclear.
  • Limited data exists on the specific benefits and risks of this treatment in this critical patient population.

Purpose of the Study:

  • To evaluate the safety and efficacy of intravenous beta-blockers in STEMI patients undergoing primary PCI.
  • To synthesize evidence from randomized trials on key clinical outcomes.

Main Methods:

  • Systematic search of electronic databases for randomized controlled trials.
  • Inclusion criteria: STEMI patients undergoing primary PCI, comparing intravenous beta-blockers with routine care or placebo.
  • Meta-analysis using DerSimonian and Laird random-effects model to calculate summary risk ratios (RR).

Main Results:

  • Four trials involving 1149 Killip class I or II STEMI patients were analyzed.
  • Intravenous beta-blockers significantly reduced the risk of ventricular arrhythmias (RR 0.42, P=0.001).
  • No significant differences were observed in cardiogenic shock, bradycardia, all-cause mortality, or cardiovascular mortality. A trend towards reduced future heart failure hospitalizations was noted (RR 0.32, P=0.06).

Conclusions:

  • Intravenous beta-blockers appear safe for STEMI patients (Killip class I/II) undergoing primary PCI.
  • A reduction in ventricular arrhythmias was observed, but the impact on other outcomes requires further investigation due to small sample sizes.
  • Larger trials are recommended to definitively establish the efficacy of intravenous beta-blockers in the primary PCI setting.
Abstract

Keywords:
Adrenergic beta-antagonistsMeta-analysisMyocardial infarctionPercutaneous coronary intervention

More Related Videos

The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

25.6K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
386
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K